XML 62 R51.htm IDEA: XBRL DOCUMENT v3.19.1

Related Party Transactions (Details Narrative) $ / shares in Units, $ in Thousands							1 Months Ended		8 Months Ended	12 Months Ended
	Dec. 26, 2017 USD ($)	Nov. 17, 2017	Nov. 07, 2017	Aug. 11, 2017 USD ($)	Jul. 09, 2017 USD ($)	Jun. 23, 2017 USD ($)	Jul. 31, 2018 USD ($)	Apr. 30, 2018	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) Products $ / shares shares
Common stock issued | shares									6,000,000	17,607,928
Common stock par value per share | $ / shares									$ 0.001	$ 0.001
Number of stock options issued to purchase common stock | shares										225,000
Stock-based compensation expense									$ 1,761	$ 1,850
Payment of research and development expense									3,930	$ 5,627
Credit agreement term		10 years	10 years
Restricted Stock [Member]
Number of stock options issued to purchase common stock | shares										218,980
Research and Development Expense [Member]
Stock-based compensation expense									26	$ 80
Harrow Health Inc [Member]
Common stock issued | shares										3,500,000
Common stock par value per share | $ / shares										$ 0.001
Number of products | Products										2
Harrow Health Inc [Member] | Stock Option [Member]
Stock-based compensation expense									112	$ 51
Harrow Health Inc [Member] | Common Stock [Member]
Restricted stock award forfeited | shares										20,000
Percentage of restricted stock and option vested								100.00%
Harrow Health Inc [Member] | Restricted Stock [Member]
Number of restricted common stock issued for services | shares										1,500,000
Number of stock options issued to purchase common stock | shares										130,000
Stock-based compensation expense									$ 1,370	$ 970
Harrow Health Inc [Member] | Licensing Agreement [Member]
Related party transaction							$ 50
Harrow Health Inc [Member] | Research and Development Expense [Member]
Related party transaction	$ 50
Harrow Health Inc [Member] | Patents [Member]
Related party transaction										$ 50
Royalty fee percentage										6.00%
Eyemax [Member]
Related party transaction				$ 250
Payment of research and development expense				250
Sale of product expense				$ 500
Related party transaction date				Aug. 11, 2017
Percentage of royalty fee				10.00%
Credit agreement term				10 years
Andersen Pharma LLC [Member]
Related party transaction					$ 750
Payment of research and development expense					750
Sale of product expense					$ 750
Related party transaction date					Jul. 09, 2017
Percentage of royalty fee					50.00%
Credit agreement term					5 years
Selenix LLC [Member]
Related party transaction						$ 1,500
Payment of research and development expense						1,500
Sale of product expense						$ 1,000
Related party transaction date						Jun. 23, 2017
Percentage of royalty fee						50.00%
Credit agreement term						10 years

X

- Definition

Credit agreement term.

+ References

No definition available.

+ Details

Name:	ETON_CreditAgreementTerm
Namespace Prefix:	ETON_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of products.

+ References

No definition available.

+ Details

Name:	ETON_NumberOfProducts
Namespace Prefix:	ETON_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Restricted stock and stock options vested.

+ References

No definition available.

+ Details

Name:	ETON_PercentageOfRestrictedStockAndStockOptionsVested
Namespace Prefix:	ETON_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty fee percentage.

+ References

No definition available.

+ Details

Name:	ETON_RoyaltyFeePercentage
Namespace Prefix:	ETON_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name:	us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of shares related to Restricted Stock Award forfeited during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_HarrowHealthIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ETON_LicensingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_EyemaxLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_AndersenPharmaLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ETON_SelenixLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: